Zai Lab partner MacroGenics announces US FDA approval of MARGENZA for patients with pretreated metastatic HER2-positive breast cancer

▴ Zai Lab partner MacroGenics announces US FDA approval of MARGENZA for patients with pretreated metastatic HER2-positive breast cancer
The approval for MARGENZA was based on data from SOPHIA, a randomized Phase 3 clinical trial

Zai Lab Limited’s partner MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is being further developed by MacroGenics for the treatment of advanced gastric cancer, with support by Zai Lab in Greater China. The approval in breast cancer in the U.S. was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial.

“We congratulate our partner MacroGenics for this great success,” said Samantha Du, PhD., Founder, Chairwoman and Chief Executive Officer of Zai Lab. “We look forward to bringing this important medicine to metastatic breast cancer patients in China as soon as possible. We are also participating in the global Phase 2/3 MAHOGANY clinical trial of margetuximab plus checkpoint blockade, with or without chemotherapy, as a potential first-line treatment for patients in front-line gastroesophageal cancer.”

The approval for MARGENZA was based on data from SOPHIA, a randomized Phase 3 clinical trial. The study, which included 536 patients, showed a statistically significant 24% reduction in the risk of disease progression or death with MARGENZA plus chemotherapy compared with trastuzumab plus chemotherapy (hazard ratio [HR]=0.76; 95% CI, 0.59-0.98; P=0.033; median PFS 5.8 vs 4.9 months). The objective response rate for MARGENZA plus chemotherapy was 22% and for trastuzumab plus chemotherapy was 16%. The final Overall Survival (OS) analysis is expected in the second half of 2021.

Adverse reactions occurring in greater than twenty percent of patients with MARGENZA in combination with chemotherapy were fatigue/asthenia (57%), nausea (33%), diarrhea (25%), and vomiting (21%). The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity. In addition, MARGENZA can cause infusion-related reactions (IRRs). IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients.

The SOPHIA study is a randomized, open-label Phase 3 clinical trial evaluating MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, who have previously been treated with anti-HER2-targeted therapies. All study patients had previously received trastuzumab, all but one patient had previously received pertuzumab, and 91% had previously received ado-trastuzumab emtansine, or T-DM1.

The study enrolled 536 patients who were randomized 1:1 to receive either MARGENZA (n=266) given intravenously at 15 mg/kg every three weeks or trastuzumab (n=270) given intravenously at 6 mg/kg (or 8 mg/kg for loading dose) every three weeks in combination with one of four chemotherapy agents (capecitabine, eribulin, gemcitabine or vinorelbine) given at the standard doses. Intent-to-treat PFS analysis occurred after 265 PFS events.

The primary endpoints of the study are sequentially assessed PFS, determined by blinded, centrally reviewed radiological review, followed by OS. Additional key secondary endpoints are PFS by investigator assessment, ORR and Duration of Response. Tertiary endpoints include ORR by investigator assessment and safety. PFS and ORR were assessed according to Response Evaluation Criteria in Solid Tumours version.

Tags : #ZaiLab #MacroGenics #LatestResearchonBreastCancer17thDec #LatestUSFDAApproval17thDec #LatestPharmaNews17thDec #BreastCancerandChemotherapy

About the Author


Team Medicircle

Related Stories

04 Apr

Strength Doesn’t Retire: The Science Behind Ageless Power

Older adults can not only participate in strength training but may also experience less muscle soreness and damage than younger individuals.

View
04 Apr

Beyond the Baby Bump: Can Delayed Pregnancy Increase Autism Risk in Children

Rather than discouraging older women from conceiving, the focus should be on education, preparation, and providing comprehensive prenatal care.

View
03 Apr

The Daily Shower Debate: Are You Washing Away Your Skin’s Health?

Adopting a mindful approach, such as choosing gentle skincare products, limiting shower time, and maintaining hydration, can ensure that your hygiene routine works in harmony with your body’s natural needs.

View
03 Apr

Is This the Future of Physiotherapy? Inside Stance Health’s $1M Expansion

With the right mix of expertise, funding, and innovation, the company will not just be filling a gap but also build a future where effective MSK care is accessible to all.

View
02 Apr

DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?

As the healthcare landscape evolves, initiatives like these will determine the future of medical care in the country.

View
02 Apr

World Autism Awareness Day: Breaking the Chains of Stigma in India

Are we ready to create a world that embraces neurodiversity, or will we continue to let ignorance dictate the lives of millions?

View
02 Apr

The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time Rest

By implementing screen-free bedtime routines, reducing blue light exposure, and prioritizing sleep hygiene, we can reclaim the restful nights we deserve.

View
02 Apr

From Scroll to Squint: How Reels Are Reshaping Your Vision

By adopting healthier screen habits and prioritizing eye care, we can prevent the irreversible damage caused by prolonged digital exposure.

View
02 Apr

High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?

It’s time to prioritize human life over convenience and invest in smarter urban designs to empower communities with the knowledge and tools needed to act swiftly in times of crisis.

View
01 Apr

Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early Detection

Medanta Gurugram—India’s leading multi-speciality hospital, ranked as the country’s best private hospital by Newsweek for six consecutive years—took colon cancer awareness to the next level with its innovative and engaging initiative, “Colon Tunnel on Wheels

View

-Advertisements-




Trending Now

Strength Doesn’t Retire: The Science Behind Ageless PowerApril 04, 2025
Beyond the Baby Bump: Can Delayed Pregnancy Increase Autism Risk in ChildrenApril 04, 2025
University of Manchester invites applications for MA Social AnthropologyApril 03, 2025
Ahead of World Health Day, Sova Health Launches Advanced Microbiome Tests & Evidence-Based Precision Supplements April 03, 2025
Half of women cannot make decisions about their reproductive health and bodily autonomyApril 03, 2025
UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM* April 03, 2025
SF Airlines Entrusts Çelebi India with Freighter Handling at Kempegowda International Airport, BengaluruApril 03, 2025
Is This the Future of Physiotherapy? Inside Stance Health’s $1M ExpansionApril 03, 2025
The Daily Shower Debate: Are You Washing Away Your Skin’s Health?April 03, 2025
The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025